These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35383291)

  • 41. TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population.
    Mohammed Basabaeen AA; Abdelgader EA; Babekir EA; Abdelrahim SO; Eltayeb NH; Altayeb OA; Fadul EA; Sabo A; Ibrahim IK
    Asian Pac J Cancer Prev; 2019 May; 20(5):1579-1585. PubMed ID: 31128065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.
    Liu E; Sudha P; Becker N; Jaouadi O; Suvannasankha A; Lee K; Abonour R; Abu Zaid M; Walker BA
    Blood Cancer J; 2023 Sep; 13(1):144. PubMed ID: 37696786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring the hub genes and potential drugs involved in Fanconi anemia using microarray datasets and bioinformatics analysis.
    Hameed AR; Fakhri Ali S; N Almanaa T; Aljasir MA; Alruwetei AM; Sanami S; Ayaz H; Ali I; Ahmad F; Ahmad S
    J Biomol Struct Dyn; 2023 Dec; ():1-14. PubMed ID: 38149868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.
    Novak ER; Deshpande A; Finlay D; Mason JR; Deshpande AJ; Adams PD; Li S
    Methods Mol Biol; 2023; 2594():87-95. PubMed ID: 36264490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research.
    Kunst N; Stout NK; O'Brien G; Christensen KD; McMahon PM; Wu AC; Diller LR; Yeh JM
    J Natl Cancer Inst; 2022 May; 114(5):722-731. PubMed ID: 35043946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
    Ben-Cohen G; Doffe F; Devir M; Leroy B; Soussi T; Rosenberg S
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35043155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p53Transfectants in Ovarian Cancer.
    Vikhanskaya F; Broggini M
    Methods Mol Med; 2001; 39():187-91. PubMed ID: 21340771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia
    Soussi T; Baliakas P
    Front Oncol; 2022; 12():808886. PubMed ID: 35251978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.
    Wood AC; Zhang Y; Mo Q; Cen L; Fontaine J; Hoffe SE; Frakes J; Dineen SP; Pimiento JM; Walko CM; Mehta R
    Oncologist; 2022 Apr; 27(4):307-313. PubMed ID: 35380714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma.
    Saghaeiannejad Esfahani H; Vela CM; Chauhan A
    Front Oncol; 2021; 11():653153. PubMed ID: 34141612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
    Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
    Nat Med; 2020 Oct; 26(10):1549-1556. PubMed ID: 32747829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
    Morabito F; Gentile M; Monti P; Recchia AG; Menichini P; Skafi M; Atrash M; De Luca G; Bossio S; Al-Janazreh H; Galimberti S; Salah Z; Morabito L; Mujahed A; Hindiyeh M; Dono M; Fais F; Cutrona G; Neri A; Tripepi G; Fronza G; Ferrarini M
    Expert Opin Investig Drugs; 2020 Aug; 29(8):869-880. PubMed ID: 32551999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
    Batır MB; Şahin E; Çam FS
    Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
    Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
    Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
    [No Abstract]   [Full Text] [Related]  

  • 59. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
    Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
    Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.